Human RCTs suggest GLP-1 drugs lead to ~40% of weight loss coming from lean mass, vs ~25% with lifestyle interventions
The clinical program is minimal no lab testing, no dietitian access, and low ongoing support
The semaglutide component follows the same dose escalation schedule as standard compounded semaglutide: Weeks 1-4: 0.25 mg semaglutide (0.1 mL) Weeks 5-8: 0.5 mg semaglutide (0.2 mL) Weeks 9-12: 1.0 mg semaglutide (0.4 mL) Weeks 13-16: 1.7 mg semaglutide (0.68 mL) Week 17+: 2.4 mg semaglutide (0.96 mL) The niacinamide dose scales proportionally with the injection volume
We also specialize in menopause and perimenopause
In an MMRM, the missing values are automatically accounted for using a missing-at-random assumption
Over time, insulin resistance can lead to further complications, including impaired glucose tolerance, type 2 diabetes, and cardiovascular disease